Last reviewed · How we verify
VX-880
VX-880 is a stem cell therapy that aims to restore vision in patients with advanced retinitis pigmentosa.
VX-880 is a stem cell therapy that aims to restore vision in patients with advanced retinitis pigmentosa. Used for Treatment of advanced retinitis pigmentosa.
At a glance
| Generic name | VX-880 |
|---|---|
| Also known as | Zimislecel, Formerly known as STx-02 |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Modality | Biologic |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
VX-880 uses induced pluripotent stem cells (iPSCs) to generate retinal pigment epithelial cells, which are then transplanted into the retina to replace damaged cells and restore vision. This approach has shown promise in preclinical studies and is currently being investigated in clinical trials.
Approved indications
- Treatment of advanced retinitis pigmentosa
Common side effects
- Unknown
Key clinical trials
- An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant (PHASE3)
- A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VX-880 CI brief — competitive landscape report
- VX-880 updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI